

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 31 of December 2024

	31.12.2024	31.12.2023
	<i>BGN'000</i>	<i>BGN'000</i>
ASSETS		
Non-current assets		
Property, plant and equipment	33 336	33 083
Intangible assets	3 556	3 560
Investments in subsidiaries	69	19
Trade receivables	5 403	4 978
Total non-current assets	42 364	41 640
Current assets		
Inventories	15 862	14 303
Trade and other receivables	68 479	66 490
Current corporate income tax	-	12
Cash and cash equivalents	79	60
Total current assets	84 420	80 865
Total assets	126 784	122 505
LIABILITIES		
Equity		
Share capital	91 800	84 500
Reserves	13 147	12 800
Retained earnings	5 098	7 707
Total	110 045	105 007
Non-current liabilities		
Long-term loans	942	879
Deferred tax liabilities	1 113	1 113
Retirement benefit obligations	173	197
Total non-current liabilities	2 228	2 189
Current liabilities		
Trade and other liabilities	4 201	4 768
Short-term loans	9 784	9 791
Current portion of long-term loans	403	507
Other tax liabilities	123	243
Total current liabilities	14 511	15 309
Total liabilities	16 739	17 498
Total equity and liabilities	126 784	122 505

Date of preparation: 23.01.2025

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 31 of December 2024

	31.12.2024	31.12.2023
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	53 141	48 512
Other income	231	74
Total income	53 372	48 586
Carrying amount of goods sold	(2 251)	(862)
Changes in inventories of finished products and work in progress	(79)	(233)
Materials and services	(33 058)	(32 441)
Personnel expenses	(9 087)	(7 333)
Depreciation / amortisation expenses	(2 519)	(2 809)
Other expenses	(528)	(899)
Finance income	530	537
Finance costs	(757)	(676)
Total expenses	(47 749)	(44 716)
Profit before taxation	5 623	3 870
Corporate income tax expense	(585)	(470)
Profit/Loss for the period	5 038	3 400
		18
Total comprehensive income for the period	5 038	3 418
Earnings per share / in BGN per 1 share /	0.05	0.04

Date of preparation: 23.01.2025

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 31 of December 2024

	31.12.2024	31.12.2023
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	40 546	33 521
Payments to suppliers of materials, goods and services	(20 986)	(18 136)
Payments to personnel	(9 193)	(6 580)
Foreign currency exchange gains/losses	(48)	(23)
Payments of interest and dividends	(573)	(393)
Other proceeds / payments	(6 381)	(5 522)
Net cash flows	3 365	2 867
Cash flows from investing activities		
Payments on non-current assets acquired	(2 168)	(1 912)
Other post/payments for investment activity	(50)	-
Net cash flows	(2 218)	(1 912)
Cash flows from financial activities		
Proceeds from loans	592	527
Payments on loans	(597)	(527)
Payment of interest, dividends	(601)	(499)
Payments on finance lease	(522)	(522)
Net cash flows	(1 128)	(1 021)
Change in cash and cash equivalents	19	(66)
Cash and cash equivalents at the beginning of the period	60	126
Cash and cash equivalents at the end of the period	79	60

Date of preparation: 23.01.2025

Sofia

Prepared by:.....
 / P. Moneva /

Executive
 Director:.....
 /B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 31 of December 2024

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2023	84 500	4 351	8 147	4 591	101 589
Profit/loss for the period				3 400	3 400
Other comprehensive income		18			18
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		18		3 400	3 400
Issue of shares by the owners			284	(284)	
Dividends accrued			284	(284)	
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period					
Balance as of 31.12.2023	84 500	4 369	8 431	7 707	105 007
Balance as of 01.01.2024	84 500	4 369	8 431	7 707	105 007
Profit/loss for the period				5 038	5 038
Other comprehensive income					
Total comprehensive income				5 038	5 038
Issue of shares by the owners	7 300		347	(7 647)	
Total amount of income and expenses recognised during the period	7 300		347	(7 647)	
Balance as of 31.12.2024	91 800	4 369	8 778	5 098	110 045

Date of preparation: 23.01.2025
Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev/